Literature DB >> 6938261

Buffy coat autografts for patients with chronic granulocytic leukaemia in transformation.

J M Goldman, D Catovsky, A W Goolden, S A Johnson, D A Galton.   

Abstract

We have treated 20 patients with chronic granulocytic leukaemia (CGL) in transformation with cytotoxic drugs or with cytotoxic drugs and whole-body irradiation followed by transfusion of autologous blood cells collected at diagnosis and stored in liquid nitrogen. The mean number of nucleated cells autografted was 25.1 X 10(8)/kg (range: 12.5-40.1). Full myeloid engraftment occurred in 18 patients; it was partial in one patient and unassessable in another. The median survival for the 20 patients post-graft was 14 weeks. Two patients are alive, one now in recurrent transformation, and one in second chronic phase that has lasted 52 weeks. For the 18 patients who died the mean survival was 24 weeks (range: 2-125). Two patients with predominantly myelosclerotic transformation showed evidence of engraftment. One patient successfully autografted developed features consistent with graft-versus-host disease which proved fatal. We conclude that autografting may offer substantial palliation for some but not all patients with CGL in transformation.

Entities:  

Mesh:

Year:  1981        PMID: 6938261     DOI: 10.1007/bf01026384

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  16 in total

1.  Autografting cryopreserved buffy coat cells for chronic granulocytic leukaemia in transformation.

Authors:  J M Goldman
Journal:  Exp Hematol       Date:  1979       Impact factor: 3.084

2.  Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow.

Authors:  C D Buckner; P Stewart; R A Clift; A Fefer; P E Neiman; J Singer; R Storb; E D Thomas
Journal:  Exp Hematol       Date:  1978-01       Impact factor: 3.084

3.  Treatment of blastic transformation of chronic granulocytic leukemia by high dose cyclophosphamide, total body irradiation and infusion of cryopreserved autologous marrow.

Authors:  C D Buckner; R A Clift; A Fefer; P E Neiman; R Storb; E D Thomas
Journal:  Exp Hematol       Date:  1974       Impact factor: 3.084

4.  Haemopoietic stem cell autografts for leukaemia.

Authors:  J M Goldman
Journal:  Blut       Date:  1980-08

5.  Graft-versus-host disease in recipients of syngeneic bone marrow.

Authors:  E Gluckman; A Devergie; J Sohier; J H Saurat
Journal:  Lancet       Date:  1980-02-02       Impact factor: 79.321

6.  Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol).

Authors:  I Cunningham; T Gee; M Dowling; R Chaganti; R Bailey; S Hopfan; L Bowden; A Turnbull; W Knapper; B Clarkson
Journal:  Blood       Date:  1979-03       Impact factor: 22.113

7.  Karyotypic conversion in Ph1-positive chronic myeloid leukaemia with combination chemotherapy.

Authors:  J C Sharp; M V Joyner; A W Wayne; J Kemp; M Crofts; A D Birch; G McArthur; S Lai; H Sterndale; Y Williams
Journal:  Lancet       Date:  1979-06-30       Impact factor: 79.321

8.  Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies.

Authors:  M Coleman; R T Silver; T F Pajak; F Cavalli; K R Rai; J E Kostinas; O Glidewell; J F Holland
Journal:  Blood       Date:  1980-01       Impact factor: 22.113

9.  Treatment of chronic granulocytic leukemia by chemotherapy, total body irradiation and allogeneic bone marrow transplantation.

Authors:  K Doney; C D Buckner; G E Sale; R Ramberg; C Boyd; E D Thomas
Journal:  Exp Hematol       Date:  1978-10       Impact factor: 3.084

10.  The cryopreservation of leukaemia cells: morphological and functional changes.

Authors:  R M Lowenthal; D S Park; J M Goldman; R S Hill; G Whyte; K H Th'ng
Journal:  Br J Haematol       Date:  1976-09       Impact factor: 6.998

View more
  1 in total

1.  Circulating hematopoietic progenitors in patients with primary lung cancer.

Authors:  E Shimizu; J N Mukai; Y Takaue; T Ogura
Journal:  Jpn J Cancer Res       Date:  1990-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.